Literature DB >> 25845873

Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.

J B Pain1, M P Lê2, M Caseris3, C Amiel4, L Lassel5, C Charpentier6, A Desnoyer1, C Farnoux7, G Pialoux8, D Descamps6, G Peytavin9.   

Abstract

We describe the pharmacokinetics of dolutegravir (DTG) in a premature neonate after maternal intensification of an antiretroviral (ARV) regimen by adding DTG. During the last 2 weeks of pregnancy, the ARV was tenofovir-emtricitabine, atazanavir-ritonavir, and DTG (50 mg once daily). From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25845873      PMCID： PMC4432130          DOI： 10.1128/AAC.00173-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

Authors:  Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Amanda H Corbett; Angela D M Kashuba
Journal:  Biomed Chromatogr       Date:  2007-10       Impact factor: 1.902

2.  Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

Authors:  Ivy Song; Julie Borland; Shuguang Chen; Yu Lou; Amanda Peppercorn; Toshihiro Wajima; Sherene Min; Stephen C Piscitelli
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

3.  The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver.

Authors:  Shogo J Miyagi; Abby C Collier
Journal:  Drug Metab Dispos       Date:  2011-01-25       Impact factor: 3.922

4.  Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

Authors:  Jelena Ivanovic; Emanuele Nicastri; Maurizio M Anceschi; Paolo Ascenzi; Fabrizio Signore; Giuseppe Pisani; Cristina Vallone; Elisabetta Mattia; Stefania Notari; Massimo Tempestilli; Leopoldo P Pucillo; Pasquale Narciso
Journal:  Curr HIV Res       Date:  2009-11       Impact factor: 1.581

Review 5.  Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.

Authors:  Abhishek Gulati; Phillip M Gerk
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534
  5 in total
  12 in total

Review 1.  Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Authors:  Amy L Slogrove; Polly Clayden; Elaine J Abrams
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

2.  Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.

Authors:  Lisa Rahangdale; Jordan Cates; JoNell Potter; Martina L Badell; Dominika Seidman; Emilly S Miller; Jenell S Coleman; Gweneth B Lazenby; Judy Levison; William R Short; Sigal Yawetz; Andrea Ciaranello; Elizabeth Livingston; Lunthita Duthely; Bassam H Rimawi; Jean R Anderson; Elizabeth M Stringer
Journal:  Am J Obstet Gynecol       Date:  2016-03       Impact factor: 8.661

3.  Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

Authors:  Nikki Mulligan; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Shelley L Buschur; Edward P Acosta; Elizabeth Smith; Nahida Chakhtoura; Sandra Burchett; Mark Mirochnick
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

4.  Dolutegravir in pregnancy-effects on HIV-positive women and their infants.

Authors:  Riikka Bornhede; Sandra Soeria-Atmadja; Katarina Westling; Karin Pettersson; Lars Navér
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-02       Impact factor: 3.267

5.  Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.

Authors:  Andrew Hill; Polly Clayden; Claire Thorne; Rachel Christie; Rebecca Zash
Journal:  J Virus Erad       Date:  2018-04-01

6.  Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).

Authors:  Catriona Waitt; Catherine Orrell; Stephen Walimbwa; Yashna Singh; Kenneth Kintu; Bryony Simmons; Julian Kaboggoza; Mary Sihlangu; Julie-Anne Coombs; Thoko Malaba; Josaphat Byamugisha; Alieu Amara; Joshua Gini; Laura Else; Christie Heiburg; Eva Maria Hodel; Helen Reynolds; Ushma Mehta; Pauline Byakika-Kibwika; Andrew Hill; Landon Myer; Mohammed Lamorde; Saye Khoo
Journal:  PLoS Med       Date:  2019-09-20       Impact factor: 11.069

7.  Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.

Authors:  Laurent Mandelbrot; Pierre-François Ceccaldi; Dominique Duro; Minh Lê; Lucile Pencolé; Gilles Peytavin
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

Review 8.  Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS.

Authors:  Huda Taha; Archik Das; Satyajit Das
Journal:  Infect Drug Resist       Date:  2015-10-01       Impact factor: 4.003

9.  Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.

Authors:  Joseph M Lewis; Eimear Railton; Andrew Riordan; Saye Khoo; Mas Chaponda
Journal:  AIDS       Date:  2016-05-15       Impact factor: 4.177

10.  A Single-Center Retrospective Cohort Analysis of Maternal and Infant Outcomes in HIV-Infected Mothers Treated with Integrase Inhibitors During Pregnancy.

Authors:  Monique L Mounce; Laura Pontiggia; Jessica L Adams
Journal:  Infect Dis Ther       Date:  2017-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.